Global Myelodysplastic Syndrome (MDS) Drugs Market 2018 by Manufacturers, Countries, Type and Application, Forecast to 2023

August 2018 | 109 pages | ID: GE686188C11GEN
GlobalInfoResearch

Abstracts

Myelodysplastic syndrome is caused by mutation of one or more genes that control development of blood cells. It is one of the most common malignant hematological diseases that affects five out of every 100,000 people in U.S. annually. An estimated 60,000 people in U.S. live with MDS, and approximately 10,000-15,000 new cases are reported each year. Patients may present with clinical manifestations such as thrombocytopenia, neutropenia, and anemia. Exposure to chemicals (such as pesticides, tobacco, and benzene) and heavy metals (such as mercury and lead) may trigger disease onset.

SCOPE OF THE REPORT:

This report studies the Myelodysplastic Syndrome (MDS) Drugs market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Myelodysplastic Syndrome (MDS) Drugs market by product type and applications/end industries.
In recent years, demand for hypomethylating agents has been at a high due to approval and adoption of Vidaza and Dacogen. A strong pipeline including Aranesp is expected to boost market growth in the near future. Easy availability of and access to novel treatments in major countries provides strong commercial opportunities to the market.
The global Myelodysplastic Syndrome (MDS) Drugs market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.

The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.

North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Myelodysplastic Syndrome (MDS) Drugs.

Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.

Market Segment by Companies, this report covers

• Celgene
• Amgen
• Otsuka
• Takeda

Market Segment by Regions, regional analysis covers

• North America (United States, Canada and Mexico)
• Europe (Germany, France, UK, Russia and Italy)
• Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
• South America (Brazil, Argentina, Colombia)
• Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers

• Hypomethylating Agents
• Immunomodulatory Drugs
• Anti-anemics

Market Segment by Applications, can be divided into

• Original
• Generics

Contents

1 MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET OVERVIEW

1.1 Product Overview and Scope of Myelodysplastic Syndrome (MDS) Drugs
1.2 Classification of Myelodysplastic Syndrome (MDS) Drugs by Types
  1.2.1 Global Myelodysplastic Syndrome (MDS) Drugs Revenue Comparison by Types (2017-2023)
  1.2.2 Global Myelodysplastic Syndrome (MDS) Drugs Revenue Market Share by Types in 2017
  1.2.3 Hypomethylating Agents
  1.2.4 Immunomodulatory Drugs
  1.2.5 Anti-anemics
1.3 Global Myelodysplastic Syndrome (MDS) Drugs Market by Application
  1.3.1 Global Myelodysplastic Syndrome (MDS) Drugs Market Size and Market Share Comparison by Applications (2013-2023)
  1.3.2 Original
  1.3.3 Generics
1.4 Global Myelodysplastic Syndrome (MDS) Drugs Market by Regions
  1.4.1 Global Myelodysplastic Syndrome (MDS) Drugs Market Size (Million USD) Comparison by Regions (2013-2023)
  1.4.1 North America (USA, Canada and Mexico) Myelodysplastic Syndrome (MDS) Drugs Status and Prospect (2013-2023)
  1.4.2 Europe (Germany, France, UK, Russia and Italy) Myelodysplastic Syndrome (MDS) Drugs Status and Prospect (2013-2023)
  1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Myelodysplastic Syndrome (MDS) Drugs Status and Prospect (2013-2023)
  1.4.4 South America (Brazil, Argentina, Colombia) Myelodysplastic Syndrome (MDS) Drugs Status and Prospect (2013-2023)
  1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Myelodysplastic Syndrome (MDS) Drugs Status and Prospect (2013-2023)
1.5 Global Market Size of Myelodysplastic Syndrome (MDS) Drugs (2013-2023)

2 MANUFACTURERS PROFILES

2.1 Celgene
  2.1.1 Business Overview
  2.1.2 Myelodysplastic Syndrome (MDS) Drugs Type and Applications
    2.1.2.1 Product A
    2.1.2.2 Product B
  2.1.3 Celgene Myelodysplastic Syndrome (MDS) Drugs Revenue, Gross Margin and Market Share (2016-2017)
2.2 Amgen
  2.2.1 Business Overview
  2.2.2 Myelodysplastic Syndrome (MDS) Drugs Type and Applications
    2.2.2.1 Product A
    2.2.2.2 Product B
  2.2.3 Amgen Myelodysplastic Syndrome (MDS) Drugs Revenue, Gross Margin and Market Share (2016-2017)
2.3 Otsuka
  2.3.1 Business Overview
  2.3.2 Myelodysplastic Syndrome (MDS) Drugs Type and Applications
    2.3.2.1 Product A
    2.3.2.2 Product B
  2.3.3 Otsuka Myelodysplastic Syndrome (MDS) Drugs Revenue, Gross Margin and Market Share (2016-2017)
2.4 Takeda
  2.4.1 Business Overview
  2.4.2 Myelodysplastic Syndrome (MDS) Drugs Type and Applications
    2.4.2.1 Product A
    2.4.2.2 Product B
  2.4.3 Takeda Myelodysplastic Syndrome (MDS) Drugs Revenue, Gross Margin and Market Share (2016-2017)

3 GLOBAL MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET COMPETITION, BY PLAYERS

3.1 Global Myelodysplastic Syndrome (MDS) Drugs Revenue and Share by Players (2013-2018)
3.2 Market Concentration Rate
  3.2.1 Top 5 Myelodysplastic Syndrome (MDS) Drugs Players Market Share
  3.2.2 Top 10 Myelodysplastic Syndrome (MDS) Drugs Players Market Share
3.3 Market Competition Trend

4 GLOBAL MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET SIZE BY REGIONS

4.1 Global Myelodysplastic Syndrome (MDS) Drugs Revenue and Market Share by Regions
4.2 North America Myelodysplastic Syndrome (MDS) Drugs Revenue and Growth Rate (2013-2018)
4.3 Europe Myelodysplastic Syndrome (MDS) Drugs Revenue and Growth Rate (2013-2018)
4.4 Asia-Pacific Myelodysplastic Syndrome (MDS) Drugs Revenue and Growth Rate (2013-2018)
4.5 South America Myelodysplastic Syndrome (MDS) Drugs Revenue and Growth Rate (2013-2018)
4.6 Middle East and Africa Myelodysplastic Syndrome (MDS) Drugs Revenue and Growth Rate (2013-2018)

5 NORTH AMERICA MYELODYSPLASTIC SYNDROME (MDS) DRUGS REVENUE BY COUNTRIES

5.1 North America Myelodysplastic Syndrome (MDS) Drugs Revenue by Countries (2013-2018)
5.2 USA Myelodysplastic Syndrome (MDS) Drugs Revenue and Growth Rate (2013-2018)
5.3 Canada Myelodysplastic Syndrome (MDS) Drugs Revenue and Growth Rate (2013-2018)
5.4 Mexico Myelodysplastic Syndrome (MDS) Drugs Revenue and Growth Rate (2013-2018)

6 EUROPE MYELODYSPLASTIC SYNDROME (MDS) DRUGS REVENUE BY COUNTRIES

6.1 Europe Myelodysplastic Syndrome (MDS) Drugs Revenue by Countries (2013-2018)
6.2 Germany Myelodysplastic Syndrome (MDS) Drugs Revenue and Growth Rate (2013-2018)
6.3 UK Myelodysplastic Syndrome (MDS) Drugs Revenue and Growth Rate (2013-2018)
6.4 France Myelodysplastic Syndrome (MDS) Drugs Revenue and Growth Rate (2013-2018)
6.5 Russia Myelodysplastic Syndrome (MDS) Drugs Revenue and Growth Rate (2013-2018)
6.6 Italy Myelodysplastic Syndrome (MDS) Drugs Revenue and Growth Rate (2013-2018)

7 ASIA-PACIFIC MYELODYSPLASTIC SYNDROME (MDS) DRUGS REVENUE BY COUNTRIES

7.1 Asia-Pacific Myelodysplastic Syndrome (MDS) Drugs Revenue by Countries (2013-2018)
7.2 China Myelodysplastic Syndrome (MDS) Drugs Revenue and Growth Rate (2013-2018)
7.3 Japan Myelodysplastic Syndrome (MDS) Drugs Revenue and Growth Rate (2013-2018)
7.4 Korea Myelodysplastic Syndrome (MDS) Drugs Revenue and Growth Rate (2013-2018)
7.5 India Myelodysplastic Syndrome (MDS) Drugs Revenue and Growth Rate (2013-2018)
7.6 Southeast Asia Myelodysplastic Syndrome (MDS) Drugs Revenue and Growth Rate (2013-2018)

8 SOUTH AMERICA MYELODYSPLASTIC SYNDROME (MDS) DRUGS REVENUE BY COUNTRIES

8.1 South America Myelodysplastic Syndrome (MDS) Drugs Revenue by Countries (2013-2018)
8.2 Brazil Myelodysplastic Syndrome (MDS) Drugs Revenue and Growth Rate (2013-2018)
8.3 Argentina Myelodysplastic Syndrome (MDS) Drugs Revenue and Growth Rate (2013-2018)
8.4 Colombia Myelodysplastic Syndrome (MDS) Drugs Revenue and Growth Rate (2013-2018)

9 MIDDLE EAST AND AFRICA REVENUE MYELODYSPLASTIC SYNDROME (MDS) DRUGS BY COUNTRIES

9.1 Middle East and Africa Myelodysplastic Syndrome (MDS) Drugs Revenue by Countries (2013-2018)
9.2 Saudi Arabia Myelodysplastic Syndrome (MDS) Drugs Revenue and Growth Rate (2013-2018)
9.3 UAE Myelodysplastic Syndrome (MDS) Drugs Revenue and Growth Rate (2013-2018)
9.4 Egypt Myelodysplastic Syndrome (MDS) Drugs Revenue and Growth Rate (2013-2018)
9.5 Nigeria Myelodysplastic Syndrome (MDS) Drugs Revenue and Growth Rate (2013-2018)
9.6 South Africa Myelodysplastic Syndrome (MDS) Drugs Revenue and Growth Rate (2013-2018)

10 GLOBAL MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET SEGMENT BY TYPE

10.1 Global Myelodysplastic Syndrome (MDS) Drugs Revenue and Market Share by Type (2013-2018)
10.2 Global Myelodysplastic Syndrome (MDS) Drugs Market Forecast by Type (2018-2023)
10.3 Hypomethylating Agents Revenue Growth Rate (2013-2023)
10.4 Immunomodulatory Drugs Revenue Growth Rate (2013-2023)
10.5 Anti-anemics Revenue Growth Rate (2013-2023)

11 GLOBAL MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET SEGMENT BY APPLICATION

11.1 Global Myelodysplastic Syndrome (MDS) Drugs Revenue Market Share by Application (2013-2018)
11.2 Myelodysplastic Syndrome (MDS) Drugs Market Forecast by Application (2018-2023)
11.3 Original Revenue Growth (2013-2018)
11.4 Generics Revenue Growth (2013-2018)

12 GLOBAL MYELODYSPLASTIC SYNDROME (MDS) DRUGS MARKET SIZE FORECAST (2018-2023)

12.1 Global Myelodysplastic Syndrome (MDS) Drugs Market Size Forecast (2018-2023)
12.2 Global Myelodysplastic Syndrome (MDS) Drugs Market Forecast by Regions (2018-2023)
12.3 North America Myelodysplastic Syndrome (MDS) Drugs Revenue Market Forecast (2018-2023)
12.4 Europe Myelodysplastic Syndrome (MDS) Drugs Revenue Market Forecast (2018-2023)
12.5 Asia-Pacific Myelodysplastic Syndrome (MDS) Drugs Revenue Market Forecast (2018-2023)
12.6 South America Myelodysplastic Syndrome (MDS) Drugs Revenue Market Forecast (2018-2023)
12.7 Middle East and Africa Myelodysplastic Syndrome (MDS) Drugs Revenue Market Forecast (2018-2023)

13 RESEARCH FINDINGS AND CONCLUSION

14 APPENDIX

14.1 Methodology
14.2 Data Source

List Of Tables

LIST OF TABLES AND FIGURES

Figure Myelodysplastic Syndrome (MDS) Drugs Picture
Table Product Specifications of Myelodysplastic Syndrome (MDS) Drugs
Table Global Myelodysplastic Syndrome (MDS) Drugs and Revenue (Million USD) Market Split by Product Type
Figure Global Myelodysplastic Syndrome (MDS) Drugs Revenue Market Share by Types in 2017
Figure Hypomethylating Agents Picture
Figure Immunomodulatory Drugs Picture
Figure Anti-anemics Picture
Table Global Myelodysplastic Syndrome (MDS) Drugs Revenue (Million USD) by Application (2013-2023)
Figure Myelodysplastic Syndrome (MDS) Drugs Revenue Market Share by Applications in 2017
Figure Original Picture
Figure Generics Picture
Table Global Market Myelodysplastic Syndrome (MDS) Drugs Revenue (Million USD) Comparison by Regions 2013-2023
Figure North America Myelodysplastic Syndrome (MDS) Drugs Revenue (Million USD) and Growth Rate (2013-2023)
Figure Europe Myelodysplastic Syndrome (MDS) Drugs Revenue (Million USD) and Growth Rate (2013-2023)
Figure Asia-Pacific Myelodysplastic Syndrome (MDS) Drugs Revenue (Million USD) and Growth Rate (2013-2023)
Figure South America Myelodysplastic Syndrome (MDS) Drugs Revenue (Million USD) and Growth Rate (2013-2023)
Figure Middle East and Africa Myelodysplastic Syndrome (MDS) Drugs Revenue (Million USD) and Growth Rate (2013-2023)
Figure Global Myelodysplastic Syndrome (MDS) Drugs Revenue (Million USD) and Growth Rate (2013-2023)
Table Celgene Basic Information, Manufacturing Base and Competitors
Table Celgene Myelodysplastic Syndrome (MDS) Drugs Type and Applications
Table Celgene Myelodysplastic Syndrome (MDS) Drugs Revenue, Gross Margin and Market Share (2016-2017)
Table Amgen Basic Information, Manufacturing Base and Competitors
Table Amgen Myelodysplastic Syndrome (MDS) Drugs Type and Applications
Table Amgen Myelodysplastic Syndrome (MDS) Drugs Revenue, Gross Margin and Market Share (2016-2017)
Table Otsuka Basic Information, Manufacturing Base and Competitors
Table Otsuka Myelodysplastic Syndrome (MDS) Drugs Type and Applications
Table Otsuka Myelodysplastic Syndrome (MDS) Drugs Revenue, Gross Margin and Market Share (2016-2017)
Table Takeda Basic Information, Manufacturing Base and Competitors
Table Takeda Myelodysplastic Syndrome (MDS) Drugs Type and Applications
Table Takeda Myelodysplastic Syndrome (MDS) Drugs Revenue, Gross Margin and Market Share (2016-2017)
Table Global Myelodysplastic Syndrome (MDS) Drugs Revenue (Million USD) by Players (2013-2018)
Table Global Myelodysplastic Syndrome (MDS) Drugs Revenue Share by Players (2013-2018)
Figure Global Myelodysplastic Syndrome (MDS) Drugs Revenue Share by Players in 2016
Figure Global Myelodysplastic Syndrome (MDS) Drugs Revenue Share by Players in 2017
Figure Global Top 5 Players Myelodysplastic Syndrome (MDS) Drugs Revenue Market Share in 2017
Figure Global Top 10 Players Myelodysplastic Syndrome (MDS) Drugs Revenue Market Share in 2017
Figure Global Myelodysplastic Syndrome (MDS) Drugs Revenue (Million USD) and Growth Rate (%) (2013-2018)
Table Global Myelodysplastic Syndrome (MDS) Drugs Revenue (Million USD) by Regions (2013-2018)
Table Global Myelodysplastic Syndrome (MDS) Drugs Revenue Market Share by Regions (2013-2018)
Figure Global Myelodysplastic Syndrome (MDS) Drugs Revenue Market Share by Regions (2013-2018)
Figure Global Myelodysplastic Syndrome (MDS) Drugs Revenue Market Share by Regions in 2017
Figure North America Myelodysplastic Syndrome (MDS) Drugs Revenue and Growth Rate (2013-2018)
Figure Europe Myelodysplastic Syndrome (MDS) Drugs Revenue and Growth Rate (2013-2018)
Figure Asia-Pacific Myelodysplastic Syndrome (MDS) Drugs Revenue and Growth Rate (2013-2018)
Figure South America Myelodysplastic Syndrome (MDS) Drugs Revenue and Growth Rate (2013-2018)
Figure Middle East and Africa Myelodysplastic Syndrome (MDS) Drugs Revenue and Growth Rate (2013-2018)
Table North America Myelodysplastic Syndrome (MDS) Drugs Revenue by Countries (2013-2018)
Table North America Myelodysplastic Syndrome (MDS) Drugs Revenue Market Share by Countries (2013-2018)
Figure North America Myelodysplastic Syndrome (MDS) Drugs Revenue Market Share by Countries (2013-2018)
Figure North America Myelodysplastic Syndrome (MDS) Drugs Revenue Market Share by Countries in 2017
Figure USA Myelodysplastic Syndrome (MDS) Drugs Revenue and Growth Rate (2013-2018)
Figure Canada Myelodysplastic Syndrome (MDS) Drugs Revenue and Growth Rate (2013-2018)
Figure Mexico Myelodysplastic Syndrome (MDS) Drugs Revenue and Growth Rate (2013-2018)
Table Europe Myelodysplastic Syndrome (MDS) Drugs Revenue (Million USD) by Countries (2013-2018)
Figure Europe Myelodysplastic Syndrome (MDS) Drugs Revenue Market Share by Countries (2013-2018)
Figure Europe Myelodysplastic Syndrome (MDS) Drugs Revenue Market Share by Countries in 2017
Figure Germany Myelodysplastic Syndrome (MDS) Drugs Revenue and Growth Rate (2013-2018)
Figure UK Myelodysplastic Syndrome (MDS) Drugs Revenue and Growth Rate (2013-2018)
Figure France Myelodysplastic Syndrome (MDS) Drugs Revenue and Growth Rate (2013-2018)
Figure Russia Myelodysplastic Syndrome (MDS) Drugs Revenue and Growth Rate (2013-2018)
Figure Italy Myelodysplastic Syndrome (MDS) Drugs Revenue and Growth Rate (2013-2018)
Table Asia-Pacific Myelodysplastic Syndrome (MDS) Drugs Revenue (Million USD) by Countries (2013-2018)
Figure Asia-Pacific Myelodysplastic Syndrome (MDS) Drugs Revenue Market Share by Countries (2013-2018)
Figure Asia-Pacific Myelodysplastic Syndrome (MDS) Drugs Revenue Market Share by Countries in 2017
Figure China Myelodysplastic Syndrome (MDS) Drugs Revenue and Growth Rate (2013-2018)
Figure Japan Myelodysplastic Syndrome (MDS) Drugs Revenue and Growth Rate (2013-2018)
Figure Korea Myelodysplastic Syndrome (MDS) Drugs Revenue and Growth Rate (2013-2018)
Figure India Myelodysplastic Syndrome (MDS) Drugs Revenue and Growth Rate (2013-2018)
Figure Southeast Asia Myelodysplastic Syndrome (MDS) Drugs Revenue and Growth Rate (2013-2018)
Table South America Myelodysplastic Syndrome (MDS) Drugs Revenue by Countries (2013-2018)
Table South America Myelodysplastic Syndrome (MDS) Drugs Revenue Market Share by Countries (2013-2018)
Figure South America Myelodysplastic Syndrome (MDS) Drugs Revenue Market Share by Countries (2013-2018)
Figure South America Myelodysplastic Syndrome (MDS) Drugs Revenue Market Share by Countries in 2017
Figure Brazil Myelodysplastic Syndrome (MDS) Drugs Revenue and Growth Rate (2013-2018)
Figure Argentina Myelodysplastic Syndrome (MDS) Drugs Revenue and Growth Rate (2013-2018)
Figure Colombia Myelodysplastic Syndrome (MDS) Drugs Revenue and Growth Rate (2013-2018)
Table Middle East and Africa Myelodysplastic Syndrome (MDS) Drugs Revenue (Million USD) by Countries (2013-2018)
Table Middle East and Africa Myelodysplastic Syndrome (MDS) Drugs Revenue Market Share by Countries (2013-2018)
Figure Middle East and Africa Myelodysplastic Syndrome (MDS) Drugs Revenue Market Share by Countries (2013-2018)
Figure Middle East and Africa Myelodysplastic Syndrome (MDS) Drugs Revenue Market Share by Countries in 2017
Figure Saudi Arabia Myelodysplastic Syndrome (MDS) Drugs Revenue and Growth Rate (2013-2018)
Figure UAE Myelodysplastic Syndrome (MDS) Drugs Revenue and Growth Rate (2013-2018)
Figure Egypt Myelodysplastic Syndrome (MDS) Drugs Revenue and Growth Rate (2013-2018)
Figure Nigeria Myelodysplastic Syndrome (MDS) Drugs Revenue and Growth Rate (2013-2018)
Figure South Africa Myelodysplastic Syndrome (MDS) Drugs Revenue and Growth Rate (2013-2018)
Table Global Myelodysplastic Syndrome (MDS) Drugs Revenue (Million USD) by Type (2013-2018)
Table Global Myelodysplastic Syndrome (MDS) Drugs Revenue Share by Type (2013-2018)
Figure Global Myelodysplastic Syndrome (MDS) Drugs Revenue Share by Type (2013-2018)
Figure Global Myelodysplastic Syndrome (MDS) Drugs Revenue Share by Type in 2017
Table Global Myelodysplastic Syndrome (MDS) Drugs Revenue Forecast by Type (2018-2023)
Figure Global Myelodysplastic Syndrome (MDS) Drugs Market Share Forecast by Type (2018-2023)
Figure Global Hypomethylating Agents Revenue Growth Rate (2013-2018)
Figure Global Immunomodulatory Drugs Revenue Growth Rate (2013-2018)
Figure Global Anti-anemics Revenue Growth Rate (2013-2018)
Table Global Myelodysplastic Syndrome (MDS) Drugs Revenue by Application (2013-2018)
Table Global Myelodysplastic Syndrome (MDS) Drugs Revenue Share by Application (2013-2018)
Figure Global Myelodysplastic Syndrome (MDS) Drugs Revenue Share by Application (2013-2018)
Figure Global Myelodysplastic Syndrome (MDS) Drugs Revenue Share by Application in 2017
Table Global Myelodysplastic Syndrome (MDS) Drugs Revenue Forecast by Application (2018-2023)
Figure Global Myelodysplastic Syndrome (MDS) Drugs Market Share Forecast by Application (2018-2023)
Figure Global Original Revenue Growth Rate (2013-2018)
Figure Global Generics Revenue Growth Rate (2013-2018)
Figure Global Myelodysplastic Syndrome (MDS) Drugs Revenue (Million USD) and Growth Rate Forecast (2018 -2023)
Table Global Myelodysplastic Syndrome (MDS) Drugs Revenue (Million USD) Forecast by Regions (2018-2023)
Figure Global Myelodysplastic Syndrome (MDS) Drugs Revenue Market Share Forecast by Regions (2018-2023)
Figure North America Myelodysplastic Syndrome (MDS) Drugs Revenue Market Forecast (2018-2023)
Figure Europe Myelodysplastic Syndrome (MDS) Drugs Revenue Market Forecast (2018-2023)
Figure Asia-Pacific Myelodysplastic Syndrome (MDS) Drugs Revenue Market Forecast (2018-2023)
Figure South America Myelodysplastic Syndrome (MDS) Drugs Revenue Market Forecast (2018-2023)
Figure Middle East and Africa Myelodysplastic Syndrome (MDS) Drugs Revenue Market Forecast (2018-2023)